---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-028574"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:34:26.771810+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio reports FY2025 net loss $1.40/sh; Phase 3 AD trial 65% enrolled

## Summary
- FY2025 net loss $1.40 basic and diluted EPS; R&D $25.2M, G&A $4.5M; cash $19.5M expected to fund into Q3 2026.
- Phase 3 AD trial (NCT06709014) 65% enrolled across 83 US sites; DSMB positive recommendation at 6-month safety review.
- Open-label extension PD study initiated Jan 2026; FDA positive recommendation for PD dementia study design discussions.
- All patents transferred to new crystal form of buntanetap, extending IP protection to 2047.
- Appointed Mark Guerin as CFO and Hui Liu as Director of Biostatistics in 2025.

## SEC filing metadata
- accession: 0001104659-26-028574
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465926028574/0001104659-26-028574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465926028574/tm268976d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-028574
- JSON: https://secwatch.observer/filing/0001104659-26-028574.json
- Plain text: https://secwatch.observer/filing/0001104659-26-028574.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.